| Literature DB >> 33103377 |
Zhezhi Deng1, Minping Li1, Junjie Guo1, Dongxiao Zhou1, Xurui Huang1, Yongxin Huang1, Haiwei Huang1.
Abstract
BACKGROUND ANDEntities:
Keywords: 25-hydroxyvitamin D3; biomarker; immune inflammatory effects; radiation-induced brain injury
Mesh:
Substances:
Year: 2020 PMID: 33103377 PMCID: PMC7749572 DOI: 10.1002/brb3.1892
Source DB: PubMed Journal: Brain Behav Impact factor: 2.708
FIGURE 1Representative MRI images of a patient with RBI. (a) T2‐weighted image showing finger‐like edema with bilateral lesions in temporal lobe and gadolinium‐enhanced T1‐weighted image show spot‐like and strip‐like enhancements with the right side. (b) T2‐weighted image showing small patchy abnormal signal shadows in bilateral temporal lobes and T1‐weighted image of the same patient
Demographic features of patients with RBI and healthy controls
| RBI ( | CTLs ( |
| |
|---|---|---|---|
| Age (year) | 54.56 ± 11.34 | 53.64 ± 10.31 | ns |
| Gender ( | |||
| Male | 16 (59.3%) | 48 (60.0%) | ns |
| Female | 11 (40.7%) | 32 (40.0%) | ns |
| BMI | 22.26 ± 2.95 | 21.71 ± 3.30 | ns |
| Season ( | |||
| Spring | 6 (22.2%) | 17 (21.3%) | ns |
| Summer | 3 (11.1%) | 10 (12.5%) | ns |
| Fall | 10 (37.0%) | 28 (35.0%) | ns |
| Winter | 8 (29.7%) | 25 (31.2%) | ns |
| Primary tumor | NPC | – | – |
| Latency of RBI (year) | 6.1 ± 2.9 | – | – |
| LENT/SOMA scale ( | – | – | |
| Grade 1 ( | 3 (29.7%) | – | – |
| Grade 2 ( | 12 (29.7%) | – | – |
| Grade 3 ( | 10 (29.7%) | – | – |
| Grade 4 ( | 2 (29.7%) | – | – |
| Lesion sites ( | |||
| Temporal lobe | 23 (85.2%) | – | – |
| Other | 4 (14.8%) | – | – |
| Symptoms ( | – | ||
| Cranial nerve palsy | 5 (18.5%) | – | – |
| Cranial hypertension symptoms | 17 (63.0%) | – | – |
| Cognitive impairment symptoms | 20 (74.1%) | – | – |
| Conduction beam damage (limb weakness and numbness) | 9 (33.3%) | – | – |
| Cerebellar injury symptoms | 6 (22.2%) | – | – |
| Sleep disorder | 18 (66.7%) | – | – |
| 25(OH)D3 level (nmol/L) | 40.39 ± 22.11 | 64.54 ± 19.89 |
|
| 25(OH)D3 level <50 nmol/L ( | 17 (63.0%) | 18 (22.5%) | |
| 25(OH)D3 level ≥50, <75 nmol/L ( | 8 (29.6%) | 40 (50.0%) | |
| 25(OH)D3 level ≥75 nmol/L ( | 2 (7.4%) | 22 (27.5%) | |
| CSF routine | |||
| CSF WBC (×106, median, range) | 5.0 (1.0–8.0) | – | – |
| CSF TP (g/L, mean ± | 0.42 ± 0.15 | – | – |
| CSF Glu (mmol/L, mean ± | 3.78 ± 0.74 | – | – |
| CSF CL (mmol/L, mean ± | 122.0 ± 1.41 | – | – |
| WBC (×109, median, range) | 4.9 (2.4–5.8) | 6.3 (3.7–8.8) | ns |
| Underlying disease | |||
| Coronary heart disease ( | 0 (0.0%) | 1 (1.2%) | ns |
| Hypertension ( | 10 (37.0%) | 27 (33.8%) | ns |
| Diabetes mellitus ( | 7 (25.9%) | 20 (25.0%) | ns |
25‐(OH)D3 levels in patients with RBI
| Variables | Mean ± | Range (nmol/L) |
|
|---|---|---|---|
| Age (years) | |||
| <60 ( | 47.08 ± 20.14 | 12.75–76.23 | |
| ≥60 ( | 29.02 ± 6.80 | 7.56–63.13 |
|
| Gender | |||
| Male ( | 48.90 ± 5.22 | 11.46–76.23 | |
| Female ( | 28.01 ± 5.50 | 7.56–63.13 |
|
| BMI | |||
| <20 ( | 40.77 ± 9.19 | 7.56–75.72 | |
| ≥20 ( | 40.26 ± 4.91 | 11.46–76.23 | .959 |
| Season ( | |||
| Spring ( | 31.51 ± 24.97 | 7.56–66.76 | |
| Summer ( | 43.86 ± 32.27 | 11.69–76.23 | |
| Fall ( | 42.09 ± 18.84 | 12.87–69.44 | |
| Winter ( | 43.62 ± 22.97 | 11.46–75.72 | .428 |
| Latency of RBI (year) | |||
| <5 ( | 27.30 ± 6.08 | 7.56–76.23 | |
| ≥5 ( | 48.09 ± 4.95 | 11.46–66.76 |
|
| LENT/SOMA scale | |||
| Grade 1–2 ( | 49.88 ± 22.43 | 11.46–52.88 | |
| Grade 3–4 ( | 28.53 ± 15.46 | 7.56–76.23 |
|
| Lesion sites | |||
| Temporal lobe ( | 41.12 ± 4.51 | 7.56–76.23 | |
| Other ( | 36.16 ± 13.92 | 12.87–75.72 | .688 |
| Symptoms | |||
| Cranial nerve palsy | |||
| With ( | 46.66 ± 6.19 | 26.63–69.44 | |
| Without ( | 38.60 ± 5.18 | 7.56–76.23 | .442 |
| Cranial hypertension symptoms | |||
| With ( | 37.14 ± 4.86 | 7.56–69.44 | |
| Without ( | 45.91 ± 8.03 | 11.46–76.23 | .329 |
| Cognitive impairment symptoms | |||
| With ( | 36.69 ± 4.65 | 11.46–76.23 | |
| Without ( | 50.96 ± 9.04 | 7.56–69.44 | .145 |
| Conduction beam damage (limb weakness and numbness) | |||
| With ( | 23.39 ± 5.94 | 7.56–61.77 | |
| Without ( | 48.89 ± 4.53 | 11.46–76.23 |
|
| Cerebellar injury symptoms | |||
| With ( | 34.81 ± 9.50 | 11.69–63.13 | |
| Without ( | 41.99 ± 4.82 | 7.56–76.23 | .494 |
| Sleep disorder | |||
| With ( | 39.12 ± 5.82 | 7.56–76.23 | |
| Without ( | 42.55 ± 6.17 | 14.45–69.08 | .705 |
| Underlying disease | |||
| With ( | 28.45 ± 5.61 | 7.56–63.13 | |
| Without ( | 48.60 ± 5.25 | 11.46–76.23 |
|
Correlation coefficients generated between serum 25‐(OH)D3 levels and clinical characteristics, CSF parameters in RBI patients
| Variables |
|
|
|---|---|---|
| Age | −.464 |
|
| BMI | .050 | .806 |
| Latency of RBI | .416 |
|
| LENT/SOMA scale | −.488 |
|
| CSF WBC | −.472 | .422 |
| CSF TP | .059 | .926 |
| CSF Glu | −.251 | .684 |
| CSF CL | −.340 | .576 |
| WBC | .038 | .936 |